Matthew Greenhawt
Concepts (533)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Food Hypersensitivity | 114 | 2025 | 286 | 32.990 |
Why?
| Peanut Hypersensitivity | 68 | 2025 | 208 | 24.980 |
Why?
| Anaphylaxis | 63 | 2025 | 161 | 23.020 |
Why?
| Desensitization, Immunologic | 45 | 2025 | 134 | 14.710 |
Why?
| Allergens | 81 | 2025 | 463 | 13.610 |
Why?
| Epinephrine | 35 | 2025 | 180 | 12.020 |
Why?
| Arachis | 48 | 2025 | 156 | 10.460 |
Why?
| Hypersensitivity | 31 | 2025 | 277 | 8.860 |
Why?
| Egg Hypersensitivity | 22 | 2024 | 47 | 8.360 |
Why?
| Cost-Benefit Analysis | 30 | 2025 | 615 | 6.130 |
Why?
| Drug Hypersensitivity | 11 | 2023 | 92 | 4.710 |
Why?
| Omalizumab | 8 | 2024 | 59 | 4.330 |
Why?
| Allergy and Immunology | 17 | 2025 | 60 | 4.170 |
Why?
| Skin Tests | 26 | 2022 | 126 | 3.900 |
Why?
| Pandemics | 22 | 2024 | 1516 | 3.890 |
Why?
| Asthma | 33 | 2024 | 2258 | 3.780 |
Why?
| Eczema | 17 | 2023 | 83 | 3.750 |
Why?
| Pneumonia, Viral | 10 | 2020 | 361 | 3.680 |
Why?
| Coronavirus Infections | 10 | 2020 | 355 | 3.660 |
Why?
| Humans | 315 | 2025 | 128896 | 3.630 |
Why?
| Vaccines | 9 | 2024 | 403 | 3.570 |
Why?
| Eosinophilic Esophagitis | 14 | 2023 | 333 | 3.520 |
Why?
| Anti-Allergic Agents | 5 | 2024 | 50 | 3.510 |
Why?
| Caregivers | 16 | 2023 | 821 | 3.380 |
Why?
| Milk Hypersensitivity | 7 | 2024 | 25 | 3.270 |
Why?
| Quality of Life | 34 | 2024 | 2706 | 3.020 |
Why?
| Immunoglobulin E | 28 | 2024 | 353 | 2.820 |
Why?
| Dermatitis, Atopic | 15 | 2024 | 335 | 2.800 |
Why?
| Child | 104 | 2025 | 20824 | 2.750 |
Why?
| Betacoronavirus | 7 | 2020 | 266 | 2.630 |
Why?
| Influenza Vaccines | 10 | 2018 | 544 | 2.580 |
Why?
| Practice Guidelines as Topic | 27 | 2024 | 1523 | 2.560 |
Why?
| Nut Hypersensitivity | 5 | 2019 | 9 | 2.400 |
Why?
| Immunotherapy | 15 | 2024 | 579 | 2.390 |
Why?
| Food | 15 | 2024 | 169 | 2.390 |
Why?
| Urticaria | 5 | 2022 | 42 | 2.300 |
Why?
| Infant | 62 | 2025 | 8994 | 2.290 |
Why?
| Health Care Costs | 6 | 2025 | 404 | 2.220 |
Why?
| Child, Preschool | 54 | 2025 | 10457 | 2.130 |
Why?
| Enterocolitis | 6 | 2020 | 33 | 2.030 |
Why?
| Hypersensitivity, Immediate | 4 | 2023 | 48 | 2.000 |
Why?
| Vaccination | 14 | 2024 | 1350 | 1.970 |
Why?
| Decision Support Techniques | 5 | 2024 | 387 | 1.960 |
Why?
| Injections, Intramuscular | 9 | 2025 | 127 | 1.870 |
Why?
| Influenza, Human | 7 | 2018 | 603 | 1.840 |
Why?
| School Health Services | 4 | 2020 | 233 | 1.730 |
Why?
| Consensus | 9 | 2024 | 644 | 1.710 |
Why?
| Milk | 9 | 2024 | 129 | 1.700 |
Why?
| United States | 52 | 2025 | 13975 | 1.660 |
Why?
| Infant Nutritional Physiological Phenomena | 7 | 2023 | 140 | 1.620 |
Why?
| Eggs | 7 | 2024 | 31 | 1.510 |
Why?
| Rhinitis, Allergic | 6 | 2024 | 44 | 1.480 |
Why?
| Plant Proteins | 2 | 2025 | 92 | 1.480 |
Why?
| Risk | 10 | 2020 | 866 | 1.460 |
Why?
| Dietary Exposure | 3 | 2019 | 8 | 1.440 |
Why?
| Antigens, Plant | 5 | 2025 | 51 | 1.380 |
Why?
| Immune Tolerance | 8 | 2024 | 348 | 1.370 |
Why?
| Patient-Centered Care | 7 | 2024 | 504 | 1.350 |
Why?
| Cost of Illness | 4 | 2024 | 290 | 1.340 |
Why?
| Quality-Adjusted Life Years | 8 | 2025 | 116 | 1.320 |
Why?
| Allergists | 7 | 2023 | 19 | 1.320 |
Why?
| Emergency Medical Services | 8 | 2024 | 562 | 1.310 |
Why?
| Self Administration | 5 | 2024 | 126 | 1.290 |
Why?
| Bronchodilator Agents | 6 | 2023 | 252 | 1.290 |
Why?
| Sympathomimetics | 2 | 2019 | 26 | 1.260 |
Why?
| Anti-Asthmatic Agents | 5 | 2021 | 377 | 1.240 |
Why?
| Surveys and Questionnaires | 23 | 2025 | 5355 | 1.230 |
Why?
| Primary Prevention | 7 | 2022 | 191 | 1.180 |
Why?
| Population Groups | 3 | 2019 | 60 | 1.180 |
Why?
| Markov Chains | 8 | 2024 | 124 | 1.170 |
Why?
| Health Literacy | 3 | 2020 | 164 | 1.160 |
Why?
| Administration, Oral | 14 | 2024 | 783 | 1.150 |
Why?
| Antibodies, Monoclonal, Humanized | 4 | 2024 | 750 | 1.150 |
Why?
| Female | 75 | 2025 | 68162 | 1.140 |
Why?
| Health Policy | 4 | 2020 | 359 | 1.110 |
Why?
| Delivery of Health Care | 6 | 2025 | 896 | 1.070 |
Why?
| Adolescent | 39 | 2025 | 20197 | 1.070 |
Why?
| Delphi Technique | 3 | 2024 | 219 | 1.070 |
Why?
| Canada | 10 | 2022 | 355 | 1.070 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 259 | 1.040 |
Why?
| Social Media | 5 | 2020 | 144 | 1.030 |
Why?
| Patient Participation | 5 | 2024 | 402 | 1.010 |
Why?
| Age Factors | 15 | 2024 | 3133 | 0.980 |
Why?
| Schools | 6 | 2021 | 441 | 0.960 |
Why?
| Male | 59 | 2025 | 63146 | 0.960 |
Why?
| Nasal Sprays | 1 | 2024 | 3 | 0.950 |
Why?
| Communication | 3 | 2020 | 839 | 0.930 |
Why?
| Clinical Trials as Topic | 5 | 2024 | 1002 | 0.930 |
Why?
| Evidence-Based Medicine | 7 | 2020 | 729 | 0.930 |
Why?
| Checklist | 2 | 2023 | 99 | 0.910 |
Why?
| Practice Patterns, Physicians' | 7 | 2023 | 1281 | 0.870 |
Why?
| Personal Protective Equipment | 2 | 2020 | 54 | 0.860 |
Why?
| Health Personnel | 3 | 2021 | 642 | 0.850 |
Why?
| Cross-Over Studies | 2 | 2025 | 513 | 0.840 |
Why?
| Rhinitis | 3 | 2022 | 152 | 0.830 |
Why?
| National Institute of Allergy and Infectious Diseases (U.S.) | 9 | 2019 | 30 | 0.810 |
Why?
| Probiotics | 2 | 2023 | 53 | 0.810 |
Why?
| Informed Consent | 1 | 2024 | 180 | 0.810 |
Why?
| United States Food and Drug Administration | 4 | 2024 | 204 | 0.810 |
Why?
| Biological Products | 2 | 2023 | 202 | 0.810 |
Why?
| Telemedicine | 5 | 2022 | 773 | 0.770 |
Why?
| Infant Formula | 2 | 2023 | 75 | 0.770 |
Why?
| Milk Proteins | 3 | 2022 | 37 | 0.770 |
Why?
| Rhinitis, Allergic, Seasonal | 2 | 2019 | 33 | 0.770 |
Why?
| Sublingual Immunotherapy | 2 | 2022 | 8 | 0.760 |
Why?
| Administration, Cutaneous | 5 | 2025 | 130 | 0.760 |
Why?
| Clinical Decision-Making | 4 | 2020 | 311 | 0.760 |
Why?
| Gastritis | 1 | 2023 | 98 | 0.750 |
Why?
| Food Labeling | 4 | 2019 | 18 | 0.750 |
Why?
| Enteritis | 1 | 2023 | 95 | 0.750 |
Why?
| Adult | 38 | 2025 | 35361 | 0.750 |
Why?
| Patient Reported Outcome Measures | 1 | 2024 | 359 | 0.730 |
Why?
| Siblings | 2 | 2019 | 220 | 0.720 |
Why?
| Nuts | 2 | 2019 | 12 | 0.720 |
Why?
| Students | 4 | 2024 | 576 | 0.710 |
Why?
| Penicillins | 2 | 2021 | 58 | 0.710 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 19 | 0.710 |
Why?
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 145 | 0.700 |
Why?
| Eosinophilia | 1 | 2023 | 207 | 0.690 |
Why?
| Treatment Outcome | 16 | 2025 | 10239 | 0.680 |
Why?
| Anti-Bacterial Agents | 4 | 2023 | 1701 | 0.670 |
Why?
| Physicians | 4 | 2021 | 846 | 0.670 |
Why?
| Dietary Proteins | 3 | 2020 | 131 | 0.660 |
Why?
| Observation | 1 | 2019 | 52 | 0.660 |
Why?
| Inservice Training | 1 | 2020 | 113 | 0.650 |
Why?
| Women's Health | 1 | 2022 | 361 | 0.650 |
Why?
| Bites and Stings | 1 | 2019 | 32 | 0.650 |
Why?
| Carmine | 2 | 2009 | 2 | 0.650 |
Why?
| Infection Control | 1 | 2020 | 138 | 0.650 |
Why?
| Aircraft | 1 | 2019 | 22 | 0.650 |
Why?
| Juglans | 1 | 2019 | 7 | 0.640 |
Why?
| Risk Reduction Behavior | 3 | 2018 | 212 | 0.640 |
Why?
| Health Knowledge, Attitudes, Practice | 5 | 2018 | 1264 | 0.640 |
Why?
| Patient Care | 1 | 2020 | 109 | 0.640 |
Why?
| Biological Therapy | 1 | 2019 | 30 | 0.630 |
Why?
| Diet | 8 | 2022 | 1205 | 0.630 |
Why?
| Job Satisfaction | 1 | 2021 | 197 | 0.630 |
Why?
| Pathology, Molecular | 1 | 2019 | 25 | 0.620 |
Why?
| Multiphasic Screening | 1 | 2018 | 2 | 0.610 |
Why?
| Protein Hydrolysates | 1 | 2018 | 7 | 0.610 |
Why?
| Evidence-Based Practice | 2 | 2020 | 214 | 0.610 |
Why?
| Health Promotion | 3 | 2023 | 712 | 0.600 |
Why?
| Immunomodulation | 2 | 2019 | 90 | 0.600 |
Why?
| Research Design | 5 | 2024 | 1038 | 0.600 |
Why?
| Insect Bites and Stings | 3 | 2025 | 14 | 0.600 |
Why?
| Population | 1 | 2018 | 33 | 0.600 |
Why?
| Polysorbates | 3 | 2023 | 40 | 0.600 |
Why?
| Watchful Waiting | 1 | 2018 | 66 | 0.590 |
Why?
| Ambulatory Care Facilities | 1 | 2020 | 226 | 0.590 |
Why?
| Burnout, Professional | 2 | 2021 | 399 | 0.580 |
Why?
| Food, Genetically Modified | 1 | 2017 | 3 | 0.580 |
Why?
| Air Travel | 2 | 2018 | 2 | 0.580 |
Why?
| Plants, Genetically Modified | 1 | 2017 | 19 | 0.570 |
Why?
| Orthomyxoviridae | 1 | 2018 | 39 | 0.570 |
Why?
| Crops, Agricultural | 1 | 2017 | 29 | 0.570 |
Why?
| Prejudice | 1 | 2018 | 69 | 0.570 |
Why?
| Administration, Sublingual | 4 | 2025 | 16 | 0.560 |
Why?
| Advisory Committees | 8 | 2024 | 231 | 0.560 |
Why?
| Animals | 25 | 2025 | 34628 | 0.540 |
Why?
| Home Care Services | 1 | 2020 | 246 | 0.540 |
Why?
| Health Services Accessibility | 2 | 2024 | 894 | 0.540 |
Why?
| Environmental Exposure | 2 | 2018 | 479 | 0.540 |
Why?
| Student Health Services | 2 | 2014 | 16 | 0.530 |
Why?
| Esophagus | 3 | 2019 | 253 | 0.520 |
Why?
| Public Health | 2 | 2020 | 493 | 0.520 |
Why?
| Administration, Intranasal | 3 | 2024 | 84 | 0.510 |
Why?
| Young Adult | 15 | 2025 | 12286 | 0.510 |
Why?
| Risk Assessment | 8 | 2023 | 3286 | 0.510 |
Why?
| Quality of Health Care | 1 | 2020 | 610 | 0.510 |
Why?
| Eosinophils | 3 | 2020 | 324 | 0.510 |
Why?
| Proton Pump Inhibitors | 5 | 2020 | 103 | 0.510 |
Why?
| Mastocytosis | 2 | 2023 | 13 | 0.500 |
Why?
| Influenza A virus | 2 | 2015 | 104 | 0.500 |
Why?
| Monitoring, Physiologic | 1 | 2017 | 265 | 0.490 |
Why?
| Trust | 1 | 2016 | 116 | 0.480 |
Why?
| Immunization | 4 | 2019 | 416 | 0.480 |
Why?
| Patient Outcome Assessment | 1 | 2016 | 128 | 0.480 |
Why?
| Psychometrics | 2 | 2022 | 681 | 0.480 |
Why?
| Breast Feeding | 6 | 2023 | 423 | 0.480 |
Why?
| Angioedema | 1 | 2015 | 17 | 0.470 |
Why?
| Health Status Indicators | 1 | 2015 | 168 | 0.470 |
Why?
| Drug Labeling | 1 | 2014 | 42 | 0.460 |
Why?
| Double-Blind Method | 5 | 2025 | 1858 | 0.450 |
Why?
| United Kingdom | 5 | 2023 | 263 | 0.450 |
Why?
| Anti-Inflammatory Agents | 1 | 2017 | 468 | 0.440 |
Why?
| Ovalbumin | 2 | 2013 | 177 | 0.440 |
Why?
| Middle Aged | 18 | 2025 | 30977 | 0.440 |
Why?
| Adrenal Cortex Hormones | 6 | 2023 | 525 | 0.430 |
Why?
| Iron-Dextran Complex | 2 | 2023 | 9 | 0.420 |
Why?
| Referral and Consultation | 2 | 2015 | 727 | 0.420 |
Why?
| Comorbidity | 4 | 2021 | 1542 | 0.420 |
Why?
| Excipients | 2 | 2023 | 53 | 0.420 |
Why?
| Mass Screening | 2 | 2019 | 1121 | 0.410 |
Why?
| Immunologic Tests | 3 | 2020 | 19 | 0.410 |
Why?
| Decision Making | 4 | 2020 | 837 | 0.410 |
Why?
| Polyethylene Glycols | 3 | 2023 | 598 | 0.410 |
Why?
| Glucocorticoids | 4 | 2020 | 570 | 0.400 |
Why?
| Cross-Sectional Studies | 8 | 2023 | 5032 | 0.400 |
Why?
| Patient Acceptance of Health Care | 4 | 2024 | 764 | 0.390 |
Why?
| Retrospective Studies | 13 | 2022 | 14546 | 0.390 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2015 | 250 | 0.390 |
Why?
| Internet | 1 | 2016 | 616 | 0.390 |
Why?
| Drug Approval | 2 | 2024 | 88 | 0.380 |
Why?
| Psychology, Educational | 1 | 2011 | 4 | 0.380 |
Why?
| Bacterial Proteins | 1 | 2017 | 829 | 0.370 |
Why?
| Feeding Behavior | 1 | 2017 | 620 | 0.370 |
Why?
| Immunologic Deficiency Syndromes | 2 | 2022 | 64 | 0.360 |
Why?
| Medical Overuse | 2 | 2021 | 30 | 0.360 |
Why?
| Diet Therapy | 3 | 2017 | 37 | 0.360 |
Why?
| Health Status Disparities | 1 | 2013 | 242 | 0.350 |
Why?
| Cohort Studies | 7 | 2024 | 5394 | 0.340 |
Why?
| Pregnancy Complications | 1 | 2015 | 487 | 0.340 |
Why?
| Time Factors | 7 | 2020 | 6568 | 0.340 |
Why?
| Mental Health | 3 | 2021 | 675 | 0.340 |
Why?
| Cattle | 3 | 2023 | 970 | 0.330 |
Why?
| Infant, Newborn | 9 | 2021 | 5704 | 0.330 |
Why?
| Disease Management | 5 | 2021 | 594 | 0.330 |
Why?
| Pigments, Biological | 1 | 2009 | 16 | 0.330 |
Why?
| Physician-Patient Relations | 4 | 2024 | 537 | 0.320 |
Why?
| Gastroenterology | 3 | 2020 | 177 | 0.320 |
Why?
| RNA, Messenger | 3 | 2021 | 2700 | 0.320 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 1840 | 0.320 |
Why?
| Weaning | 2 | 2020 | 49 | 0.310 |
Why?
| Administration, Inhalation | 3 | 2024 | 675 | 0.300 |
Why?
| Self Care | 3 | 2017 | 369 | 0.300 |
Why?
| Azithromycin | 1 | 2009 | 92 | 0.300 |
Why?
| Emergencies | 2 | 2019 | 164 | 0.290 |
Why?
| Emergency Service, Hospital | 4 | 2024 | 1977 | 0.290 |
Why?
| Chronic Disease | 4 | 2024 | 1715 | 0.280 |
Why?
| Pediatricians | 2 | 2020 | 133 | 0.280 |
Why?
| Prospective Studies | 9 | 2024 | 7060 | 0.280 |
Why?
| Health Status | 3 | 2021 | 750 | 0.280 |
Why?
| Goals | 2 | 2018 | 161 | 0.270 |
Why?
| Skin | 2 | 2025 | 737 | 0.270 |
Why?
| Australia | 4 | 2024 | 247 | 0.270 |
Why?
| Anxiety | 4 | 2021 | 947 | 0.270 |
Why?
| Pregnancy | 6 | 2023 | 6247 | 0.270 |
Why?
| Severity of Illness Index | 6 | 2021 | 2767 | 0.250 |
Why?
| Egg Proteins | 2 | 2016 | 19 | 0.250 |
Why?
| Administration, Topical | 3 | 2020 | 148 | 0.250 |
Why?
| Prevalence | 6 | 2022 | 2540 | 0.250 |
Why?
| Vaccines, Inactivated | 2 | 2018 | 69 | 0.250 |
Why?
| Self Report | 2 | 2020 | 796 | 0.240 |
Why?
| Periodicals as Topic | 2 | 2019 | 209 | 0.230 |
Why?
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2023 | 1 | 0.220 |
Why?
| Risk Factors | 9 | 2022 | 9792 | 0.220 |
Why?
| Histamine Antagonists | 2 | 2023 | 21 | 0.220 |
Why?
| Bayes Theorem | 2 | 2022 | 367 | 0.220 |
Why?
| Cooking | 1 | 2024 | 59 | 0.220 |
Why?
| Infant Food | 2 | 2022 | 66 | 0.220 |
Why?
| Healthy Volunteers | 1 | 2024 | 204 | 0.220 |
Why?
| Janus Kinase Inhibitors | 1 | 2023 | 26 | 0.220 |
Why?
| Food, Formulated | 2 | 2020 | 16 | 0.220 |
Why?
| State Medicine | 1 | 2023 | 21 | 0.210 |
Why?
| Chicago | 2 | 2022 | 51 | 0.210 |
Why?
| Insecta | 2 | 2017 | 66 | 0.210 |
Why?
| Immunologic Factors | 2 | 2022 | 227 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 7 | 2024 | 1366 | 0.210 |
Why?
| Diagnosis, Differential | 4 | 2021 | 1435 | 0.210 |
Why?
| Dilatation | 2 | 2020 | 62 | 0.210 |
Why?
| Patient Safety | 2 | 2018 | 292 | 0.210 |
Why?
| Dermatologic Agents | 1 | 2023 | 66 | 0.210 |
Why?
| Epitopes | 1 | 2025 | 466 | 0.200 |
Why?
| Emollients | 1 | 2022 | 11 | 0.200 |
Why?
| Books | 1 | 2022 | 5 | 0.200 |
Why?
| Injections | 2 | 2021 | 174 | 0.200 |
Why?
| Immunity | 1 | 2023 | 132 | 0.200 |
Why?
| Guideline Adherence | 2 | 2019 | 526 | 0.200 |
Why?
| Patient Preference | 2 | 2024 | 182 | 0.200 |
Why?
| Nasal Polyps | 1 | 2022 | 58 | 0.200 |
Why?
| Genetic Diseases, X-Linked | 1 | 2022 | 25 | 0.190 |
Why?
| Asparaginase | 1 | 2021 | 30 | 0.190 |
Why?
| Agammaglobulinemia | 1 | 2022 | 34 | 0.190 |
Why?
| Societies, Medical | 3 | 2020 | 760 | 0.190 |
Why?
| Reproducibility of Results | 3 | 2022 | 3042 | 0.190 |
Why?
| Lactation | 1 | 2023 | 168 | 0.190 |
Why?
| Vaccines, Synthetic | 1 | 2022 | 129 | 0.190 |
Why?
| Hot Temperature | 1 | 2024 | 362 | 0.190 |
Why?
| Military Medicine | 1 | 2022 | 61 | 0.190 |
Why?
| Prognosis | 3 | 2020 | 3787 | 0.190 |
Why?
| Follow-Up Studies | 4 | 2022 | 4917 | 0.190 |
Why?
| Patient Education as Topic | 2 | 2020 | 734 | 0.180 |
Why?
| Symptom Assessment | 2 | 2020 | 127 | 0.180 |
Why?
| Parents | 3 | 2023 | 1301 | 0.180 |
Why?
| Child Day Care Centers | 1 | 2021 | 34 | 0.180 |
Why?
| Immunoglobulins, Intravenous | 1 | 2022 | 131 | 0.180 |
Why?
| Drug Prescriptions | 1 | 2023 | 253 | 0.180 |
Why?
| Esophagoscopy | 2 | 2020 | 196 | 0.180 |
Why?
| Algorithms | 3 | 2021 | 1626 | 0.180 |
Why?
| Breath Tests | 2 | 2018 | 91 | 0.180 |
Why?
| Adrenergic alpha-Agonists | 1 | 2020 | 30 | 0.180 |
Why?
| Educational Personnel | 1 | 2020 | 13 | 0.170 |
Why?
| Terbutaline | 1 | 2020 | 7 | 0.170 |
Why?
| Hoarding | 1 | 2020 | 2 | 0.170 |
Why?
| Probability | 2 | 2022 | 313 | 0.170 |
Why?
| Family | 3 | 2021 | 650 | 0.170 |
Why?
| Pilot Projects | 2 | 2018 | 1545 | 0.170 |
Why?
| Gastrointestinal Microbiome | 3 | 2024 | 635 | 0.170 |
Why?
| Sinusitis | 1 | 2022 | 204 | 0.170 |
Why?
| North America | 1 | 2021 | 289 | 0.170 |
Why?
| Consensus Development Conferences as Topic | 1 | 2020 | 29 | 0.170 |
Why?
| Antibody Specificity | 2 | 2017 | 185 | 0.170 |
Why?
| beta-Lactams | 1 | 2020 | 29 | 0.170 |
Why?
| Mass Media | 1 | 2020 | 41 | 0.170 |
Why?
| Plant Bark | 1 | 2019 | 12 | 0.170 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 147 | 0.170 |
Why?
| Albuterol | 1 | 2020 | 105 | 0.170 |
Why?
| Access to Information | 1 | 2020 | 47 | 0.170 |
Why?
| Equipment Failure | 1 | 2020 | 112 | 0.160 |
Why?
| Insurance Claim Review | 1 | 2020 | 74 | 0.160 |
Why?
| Precision Medicine | 2 | 2020 | 385 | 0.160 |
Why?
| Syndrome | 2 | 2017 | 342 | 0.160 |
Why?
| Europe | 2 | 2018 | 366 | 0.160 |
Why?
| Anti-Infective Agents | 1 | 2022 | 246 | 0.160 |
Why?
| Network Meta-Analysis | 3 | 2023 | 12 | 0.160 |
Why?
| Monte Carlo Method | 1 | 2019 | 142 | 0.160 |
Why?
| Public Facilities | 1 | 2019 | 5 | 0.160 |
Why?
| Transdermal Patch | 1 | 2019 | 16 | 0.160 |
Why?
| False Negative Reactions | 1 | 2019 | 51 | 0.160 |
Why?
| Pollen | 1 | 2019 | 25 | 0.160 |
Why?
| Crying | 1 | 2019 | 16 | 0.160 |
Why?
| Infant Behavior | 1 | 2019 | 25 | 0.160 |
Why?
| False Positive Reactions | 1 | 2019 | 115 | 0.160 |
Why?
| Equipment Design | 1 | 2020 | 522 | 0.150 |
Why?
| Drugs, Generic | 1 | 2018 | 19 | 0.150 |
Why?
| Benchmarking | 1 | 2020 | 174 | 0.150 |
Why?
| Models, Economic | 1 | 2019 | 55 | 0.150 |
Why?
| Income | 2 | 2023 | 191 | 0.150 |
Why?
| Needles | 1 | 2019 | 57 | 0.150 |
Why?
| Cost Savings | 1 | 2019 | 82 | 0.150 |
Why?
| Aged, 80 and over | 3 | 2020 | 7050 | 0.150 |
Why?
| Reference Standards | 1 | 2019 | 168 | 0.150 |
Why?
| Public Health Surveillance | 1 | 2018 | 68 | 0.150 |
Why?
| Models, Econometric | 1 | 2018 | 35 | 0.150 |
Why?
| Health Planning Guidelines | 1 | 2018 | 25 | 0.150 |
Why?
| Social Determinants of Health | 1 | 2021 | 214 | 0.150 |
Why?
| New Zealand | 1 | 2018 | 46 | 0.150 |
Why?
| Exanthema | 1 | 2019 | 76 | 0.150 |
Why?
| Vomiting | 1 | 2019 | 128 | 0.150 |
Why?
| Pruritus | 3 | 2023 | 62 | 0.150 |
Why?
| Biopsy | 3 | 2019 | 1093 | 0.150 |
Why?
| Work Performance | 1 | 2018 | 6 | 0.150 |
Why?
| Respiratory Sounds | 1 | 2019 | 121 | 0.150 |
Why?
| Travel | 1 | 2019 | 123 | 0.150 |
Why?
| Virtual Reality | 1 | 2019 | 51 | 0.150 |
Why?
| Hydrolysis | 1 | 2018 | 191 | 0.150 |
Why?
| Cough | 1 | 2019 | 118 | 0.150 |
Why?
| Heparin | 1 | 2019 | 252 | 0.150 |
Why?
| Eating | 2 | 2019 | 366 | 0.140 |
Why?
| Early Medical Intervention | 1 | 2018 | 59 | 0.140 |
Why?
| Information Dissemination | 1 | 2020 | 206 | 0.140 |
Why?
| Immune Sera | 1 | 2017 | 88 | 0.140 |
Why?
| RNA, Viral | 1 | 2021 | 622 | 0.140 |
Why?
| Administration, Intravenous | 1 | 2018 | 140 | 0.140 |
Why?
| Nasal Obstruction | 1 | 2017 | 26 | 0.140 |
Why?
| Dietary Fats | 1 | 2019 | 302 | 0.140 |
Why?
| Uncertainty | 1 | 2017 | 114 | 0.140 |
Why?
| Venoms | 1 | 2017 | 30 | 0.140 |
Why?
| Mothers | 1 | 2023 | 723 | 0.140 |
Why?
| Transgenes | 1 | 2017 | 180 | 0.130 |
Why?
| Asthma, Exercise-Induced | 1 | 2016 | 10 | 0.130 |
Why?
| Arthropod Venoms | 2 | 2025 | 3 | 0.130 |
Why?
| Bronchoconstriction | 1 | 2016 | 33 | 0.130 |
Why?
| Aged | 5 | 2022 | 22035 | 0.130 |
Why?
| Behavior | 1 | 2017 | 92 | 0.130 |
Why?
| Linear Models | 2 | 2020 | 817 | 0.130 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 576 | 0.130 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 105 | 0.130 |
Why?
| Fatty Acids | 1 | 2019 | 415 | 0.130 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2022 | 544 | 0.130 |
Why?
| Drug Administration Schedule | 1 | 2018 | 760 | 0.130 |
Why?
| Observer Variation | 1 | 2016 | 321 | 0.130 |
Why?
| Environmental Pollutants | 1 | 2018 | 142 | 0.130 |
Why?
| Hospitals, Special | 1 | 2015 | 9 | 0.130 |
Why?
| Health Surveys | 2 | 2020 | 485 | 0.130 |
Why?
| Tertiary Healthcare | 1 | 2015 | 30 | 0.130 |
Why?
| Phenotype | 3 | 2020 | 3059 | 0.120 |
Why?
| Secondary Prevention | 1 | 2017 | 238 | 0.120 |
Why?
| Protein-Losing Enteropathies | 1 | 2015 | 11 | 0.120 |
Why?
| Costs and Cost Analysis | 1 | 2016 | 211 | 0.120 |
Why?
| Patient Selection | 1 | 2019 | 671 | 0.120 |
Why?
| Lymphopenia | 1 | 2015 | 60 | 0.120 |
Why?
| Computer Simulation | 1 | 2019 | 943 | 0.120 |
Why?
| Michigan | 1 | 2014 | 105 | 0.120 |
Why?
| Self Efficacy | 1 | 2018 | 377 | 0.110 |
Why?
| Inhalation | 1 | 2014 | 30 | 0.110 |
Why?
| Academic Medical Centers | 1 | 2017 | 473 | 0.110 |
Why?
| Injections, Subcutaneous | 1 | 2014 | 145 | 0.110 |
Why?
| Population Surveillance | 1 | 2017 | 428 | 0.110 |
Why?
| Hospitalization | 2 | 2021 | 2080 | 0.110 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2013 | 82 | 0.110 |
Why?
| Moscow | 2 | 2024 | 2 | 0.110 |
Why?
| Perioperative Period | 1 | 2013 | 49 | 0.110 |
Why?
| Government Regulation | 1 | 2013 | 50 | 0.110 |
Why?
| Hypertension | 1 | 2022 | 1236 | 0.110 |
Why?
| Epigenesis, Genetic | 1 | 2018 | 613 | 0.100 |
Why?
| Fontan Procedure | 1 | 2015 | 169 | 0.100 |
Why?
| Medication Adherence | 1 | 2017 | 571 | 0.100 |
Why?
| Prebiotics | 2 | 2023 | 27 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2024 | 2013 | 0.090 |
Why?
| Triticum | 1 | 2010 | 12 | 0.090 |
Why?
| Pyroglyphidae | 2 | 2022 | 20 | 0.090 |
Why?
| Biomarkers | 2 | 2020 | 3874 | 0.090 |
Why?
| Disease Progression | 2 | 2020 | 2603 | 0.090 |
Why?
| Immunization, Secondary | 1 | 2010 | 88 | 0.090 |
Why?
| Clinical Competence | 1 | 2017 | 1020 | 0.080 |
Why?
| Adrenergic Agonists | 1 | 2009 | 6 | 0.080 |
Why?
| Aviation | 1 | 2009 | 9 | 0.080 |
Why?
| Residence Characteristics | 1 | 2012 | 326 | 0.080 |
Why?
| Histamine H1 Antagonists | 1 | 2009 | 30 | 0.080 |
Why?
| Hemiptera | 1 | 2009 | 3 | 0.080 |
Why?
| Food Coloring Agents | 1 | 2009 | 2 | 0.080 |
Why?
| Lung | 2 | 2024 | 3925 | 0.080 |
Why?
| Comprehension | 1 | 2011 | 167 | 0.080 |
Why?
| Physician's Role | 1 | 2011 | 202 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2015 | 824 | 0.080 |
Why?
| Tablets | 1 | 2009 | 39 | 0.080 |
Why?
| Empathy | 1 | 2011 | 172 | 0.080 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1040 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 1 | 2013 | 1968 | 0.080 |
Why?
| Coloring Agents | 1 | 2009 | 78 | 0.080 |
Why?
| Heart Defects, Congenital | 1 | 2015 | 752 | 0.070 |
Why?
| Sex Factors | 1 | 2014 | 1947 | 0.070 |
Why?
| Stress, Psychological | 1 | 2016 | 1051 | 0.070 |
Why?
| Tryptases | 1 | 2007 | 13 | 0.070 |
Why?
| Primary Health Care | 2 | 2021 | 1661 | 0.070 |
Why?
| Cardiac Surgical Procedures | 1 | 2013 | 501 | 0.070 |
Why?
| Occupational Diseases | 1 | 2009 | 142 | 0.070 |
Why?
| Disease Susceptibility | 2 | 2020 | 338 | 0.070 |
Why?
| Vitamin D | 2 | 2022 | 384 | 0.070 |
Why?
| Patient Discharge | 2 | 2024 | 858 | 0.070 |
Why?
| Data Collection | 1 | 2009 | 652 | 0.070 |
Why?
| Risk-Taking | 1 | 2009 | 344 | 0.070 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1967 | 0.060 |
Why?
| Fast Foods | 1 | 2024 | 16 | 0.060 |
Why?
| Food Handling | 1 | 2024 | 61 | 0.060 |
Why?
| Adaptation, Psychological | 2 | 2020 | 609 | 0.060 |
Why?
| Formoterol Fumarate | 1 | 2023 | 9 | 0.060 |
Why?
| Ethanolamines | 1 | 2023 | 20 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2024 | 108 | 0.050 |
Why?
| Budesonide | 1 | 2023 | 90 | 0.050 |
Why?
| Beneficence | 1 | 2023 | 19 | 0.050 |
Why?
| Dermatophagoides pteronyssinus | 1 | 2022 | 4 | 0.050 |
Why?
| Family Characteristics | 1 | 2024 | 175 | 0.050 |
Why?
| Sample Size | 1 | 2023 | 117 | 0.050 |
Why?
| Drug Combinations | 1 | 2023 | 327 | 0.050 |
Why?
| Tacrolimus | 1 | 2023 | 145 | 0.050 |
Why?
| Ukraine | 1 | 2022 | 8 | 0.050 |
Why?
| Baths | 1 | 2022 | 17 | 0.050 |
Why?
| Dietary Fiber | 1 | 2022 | 51 | 0.050 |
Why?
| Geography | 1 | 2022 | 185 | 0.050 |
Why?
| Aftercare | 1 | 2024 | 206 | 0.050 |
Why?
| Electronic Health Records | 2 | 2021 | 966 | 0.050 |
Why?
| Fatigue | 1 | 2024 | 319 | 0.050 |
Why?
| Child, Hospitalized | 1 | 2022 | 47 | 0.050 |
Why?
| Multicenter Studies as Topic | 1 | 2022 | 287 | 0.050 |
Why?
| Universities | 1 | 2024 | 404 | 0.050 |
Why?
| Forecasting | 1 | 2023 | 363 | 0.050 |
Why?
| Russia | 1 | 2020 | 12 | 0.040 |
Why?
| History, 20th Century | 1 | 2022 | 294 | 0.040 |
Why?
| Patient Care Management | 1 | 2021 | 57 | 0.040 |
Why?
| London | 1 | 2020 | 46 | 0.040 |
Why?
| Milk, Human | 1 | 2022 | 145 | 0.040 |
Why?
| Guilt | 1 | 2020 | 13 | 0.040 |
Why?
| Professionalism | 1 | 2020 | 17 | 0.040 |
Why?
| Grief | 1 | 2020 | 37 | 0.040 |
Why?
| Risk Management | 1 | 2021 | 92 | 0.040 |
Why?
| Patient Care Planning | 1 | 2021 | 152 | 0.040 |
Why?
| Expert Testimony | 1 | 2020 | 37 | 0.040 |
Why?
| Publication Bias | 1 | 2020 | 37 | 0.040 |
Why?
| Biological Variation, Individual | 1 | 2019 | 2 | 0.040 |
Why?
| No-Observed-Adverse-Effect Level | 1 | 2019 | 6 | 0.040 |
Why?
| Health Care Rationing | 1 | 2020 | 60 | 0.040 |
Why?
| Efficiency | 1 | 2020 | 95 | 0.040 |
Why?
| Cytokines | 1 | 2007 | 1995 | 0.040 |
Why?
| Aspirin | 1 | 2022 | 379 | 0.040 |
Why?
| Immunosuppressive Agents | 1 | 2023 | 699 | 0.040 |
Why?
| Documentation | 1 | 2021 | 182 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 195 | 0.040 |
Why?
| Placebo Effect | 1 | 2019 | 57 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2020 | 189 | 0.040 |
Why?
| Spirituality | 1 | 2020 | 82 | 0.040 |
Why?
| Medical History Taking | 1 | 2019 | 119 | 0.040 |
Why?
| Hematologic Tests | 1 | 2018 | 23 | 0.040 |
Why?
| Confidence Intervals | 1 | 2019 | 318 | 0.040 |
Why?
| Th1-Th2 Balance | 1 | 2018 | 9 | 0.040 |
Why?
| Drug Delivery Systems | 1 | 2021 | 328 | 0.040 |
Why?
| Mindfulness | 1 | 2020 | 115 | 0.040 |
Why?
| Hygiene | 1 | 2018 | 30 | 0.040 |
Why?
| Staphylococcus aureus | 1 | 2022 | 429 | 0.040 |
Why?
| Poverty | 1 | 2021 | 492 | 0.040 |
Why?
| Endoscopy, Digestive System | 1 | 2019 | 120 | 0.040 |
Why?
| Hospitals | 1 | 2022 | 628 | 0.040 |
Why?
| Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| Social Behavior | 1 | 2020 | 283 | 0.040 |
Why?
| Dietetics | 1 | 2017 | 23 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2020 | 1213 | 0.030 |
Why?
| Health Care Surveys | 1 | 2019 | 560 | 0.030 |
Why?
| Societies, Scientific | 1 | 2017 | 47 | 0.030 |
Why?
| Incidence | 1 | 2024 | 2634 | 0.030 |
Why?
| Research | 1 | 2020 | 413 | 0.030 |
Why?
| Nutritional Sciences | 1 | 2017 | 42 | 0.030 |
Why?
| Protective Factors | 1 | 2017 | 90 | 0.030 |
Why?
| Bias | 1 | 2017 | 196 | 0.030 |
Why?
| Gene-Environment Interaction | 1 | 2018 | 185 | 0.030 |
Why?
| Ambulatory Care | 1 | 2020 | 509 | 0.030 |
Why?
| Child Abuse | 1 | 2021 | 518 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2019 | 491 | 0.030 |
Why?
| Immunoglobulin Isotypes | 1 | 2015 | 35 | 0.030 |
Why?
| Quality Assurance, Health Care | 1 | 2017 | 319 | 0.030 |
Why?
| Perception | 1 | 2018 | 336 | 0.030 |
Why?
| Eye Diseases | 1 | 2016 | 78 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2015 | 268 | 0.030 |
Why?
| Odds Ratio | 1 | 2017 | 1019 | 0.030 |
Why?
| Respiratory Tract Diseases | 1 | 2016 | 151 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1359 | 0.030 |
Why?
| Suicide | 1 | 2020 | 584 | 0.030 |
Why?
| Anesthesia, General | 1 | 2013 | 53 | 0.030 |
Why?
| Anesthetics | 1 | 2013 | 55 | 0.030 |
Why?
| Emotions | 1 | 2018 | 536 | 0.030 |
Why?
| Immunity, Innate | 1 | 2018 | 802 | 0.020 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2020 | 828 | 0.020 |
Why?
| Quality Improvement | 1 | 2020 | 1101 | 0.020 |
Why?
| Anesthesia | 1 | 2013 | 130 | 0.020 |
Why?
| Substance-Related Disorders | 1 | 2020 | 1019 | 0.020 |
Why?
| Diarrhea | 1 | 2012 | 179 | 0.020 |
Why?
| Depression | 1 | 2020 | 1289 | 0.020 |
Why?
| Abdominal Pain | 1 | 2012 | 144 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 2270 | 0.020 |
Why?
| Recurrence | 1 | 2013 | 1013 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3994 | 0.020 |
Why?
| Case-Control Studies | 1 | 2015 | 3334 | 0.020 |
Why?
| Signal Transduction | 1 | 2019 | 4857 | 0.020 |
Why?
|
|
Greenhawt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|